nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2013, 02, v.22 94-97
文拉法辛缓释片治疗广泛性焦虑症后的持续性注意功能改变
基金项目(Foundation): 浙江省绍兴市重点科技计划(编号2007A23019)
邮箱(Email):
DOI: 10.19577/j.cnki.issn10074406.2013.02.007
发布时间: 2013-03-25
出版时间: 2013-03-25
移动端阅读
摘要:

目的观察文拉法辛缓释片治疗广泛性焦虑症(GAD)的持续性注意力变化及临床疗效。方法 67例GAD患者以文拉法辛缓释片治疗8周,采用汉密尔顿焦虑量表(HAMA)、临床总体评价量表(CGI)评定临床疗效,以连续操作试验(CPT)检测患者治疗前后持续性注意力的变化,并将其各分项指标与67例健康对照组作对比分析。结果 67例GAD患者经文拉法辛缓释片治疗8周后,总有效率为77.5%,HAMA评分较治疗前下降明显(P<0.01)。与健康对照组相比,入组时患者组持续性注意功能有明显损害,治疗8周后的持续性注意力各分项指标较治疗前有明显改善,有些指标已接近健康对照组。结论文拉法辛缓释片治疗对GAD具有良好的疗效和安全性,其治疗后的持续性注意力有明显改善。

Abstract:

AIM To study the efficacy of venlafaxine extended release tablet on the change of continuous attention function of patients with generalized anxiety disorder(GAD).METHODS Sixty seven patients with GAD were treated with venlafaxine extended release tablet for 8 weeks.The scale of Hamilton anxiety scale(HAMA) and clinical global impression(CGI) were used to assess the efficacy,while the continuous performance test(CPT) was applied to evaluate the change of continuous attention function before and after treatment.All the items of CPT were compared with those of healthy people.RESULTS Scores of HAMA in GAD group decreased significantly after treated with venlafaxine extended release tablet,with the total effective rate of 77.5%.Compared with people in control group,GAD patients had obvious damage of continuous attention function which improved significantly after treated with venlafaxine extended release tablet.CONCLUSION Venlafaxine extended release tablet is effective and safe in treating GAD patients,which can improve their continuous attention function.

参考文献

[1]沈渔邨.精神病学[M].第4版.北京:人民卫生出版社,2002:600.

[2]袁勇贵.广泛性焦虑障碍共病研究[J].中国全科医学.2004,7(14):1100.

[3]何彦霞.焦虑症患者认知功能损害的比较研究[J].中国民康医学,2010,22(10):1218.

[4]Hackett D.Venlafaxine XR in the treatment of anxiety[J].Acta Psychiatr Scand Suppl,2000,406:30.

[5]AUgulander C,Hackett D,Salinas E.Venlafaxine extended release(ER)in the treatment of generalized anxiety disorder:twenty-four-week placebo-controlled dose-ranging study[J].Br J Psychiatry,2001,179(7):15.

[6]Davidson JR,Dupont RL,Hedges D,et al.Efficacy,safety,and tolera-??bility of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder[J].J Clin Psychiatry,1999,60(8):528.

[7]田国强,梁胜林,秦国兴.文拉法辛缓释剂与米氮平治疗难治性抑郁症的对照观察[J].中国新药与临床杂志.2007,26(9):688.

[8]甘建光,田国强,高天来.文拉法辛缓释剂对抑郁症患者认知功能的影响[J].医药导报,2010,29(4):471.

[9]田国强,甘建光,高天来.Alzheimer病持续性注意功能的相关性研究[J].中华老年医学杂志,2009,28(2):123.

[10]田国强,甘建光.强迫症患者持续性注意功能的相关性研究[J].上海精神医学,2008,20(5):268.

[11]刘延梅,于斌.王欣,等.万拉法新与氯硝安定治疗广泛性焦虑症的疗效比较[J].四川精神卫生.2006,19(2):87.

[12]程茂巧,过亚静.长期服用苯二氨(?)类药物对失眠症患者认知功能的影响[J].中国民康医学,2009,21(2):145.

基本信息:

DOI:10.19577/j.cnki.issn10074406.2013.02.007

中图分类号:R749.72

引用信息:

[1]田国强,甘建光,周芙蓉.文拉法辛缓释片治疗广泛性焦虑症后的持续性注意功能改变[J].中国临床药学杂志,2013,22(02):94-97.DOI:10.19577/j.cnki.issn10074406.2013.02.007.

基金信息:

浙江省绍兴市重点科技计划(编号2007A23019)

发布时间:

2013-03-25

出版时间:

2013-03-25

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文